Market Overview

According to fortune business insights, the global cancer biomarkers market size was valued at USD 42.87 billion in 2025. The market is projected to grow from USD 48.2 billion in 2026 to USD 83.61 billion by 2034, exhibiting a CAGR of 7.13% during the forecast period. North America dominated the cancer biomarkers market with a market share of 35.94% in 2025.

The analysis shows that top companies are investing more in cancer biomarkers due to the increasing global incidence of cancer, expanding research, and the growing use of biomarkers in drug discovery and development. These biological molecules enable early cancer detection and facilitate non-invasive diagnosis. This trend indicates a strong and growing demand for advanced diagnostic and therapeutic tools worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche Ltd.
• Abbott
• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• CENTOGENE N.V.
• Axon Medchem
• Sino Biological Inc.
• R&D System
• BioVision Inc.
• Myriad RBM
• Other players

Segments

Increasing Prevalence to Propel Breast Cancer Segment Growth

Based on cancer type, the market is divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment holds the largest market share, accounting for 32.59% in 2026, owing to its increasing prevalence and rising awareness about early diagnosis, which creates a large patient pool for diagnostic tests.

High Prevalence of Breast Cancer to Drive HER-2 Segment Expansion

By biomarker type, the market is categorized into PSA, HER-2, EGFR, KRAS, and others. The HER-2 segment is leading the market, projected to hold a 33.34% share in 2026. This is due to the rising prevalence of breast cancer and the introduction of new biomarker-based tests for diagnosis.